A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Trial Profile

A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Tamibarotene (Primary) ; Azacitidine; Azacitidine
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Biomarker; Proof of concept; Therapeutic Use
  • Sponsors Syros Pharmaceuticals
  • Most Recent Events

    • 29 Sep 2017 According to a Syros Pharmaceuticals media release, biomarker data from this study will be presented at European School of Haematologys 4th International Conference on Acute Myeloid Leukemia "Molecular and Translational": Advances in Biology and Treatment.
    • 12 Sep 2017 Results assessing PK and PD data from this trial presented at the 42nd European Society for Medical Oncology Congress
    • 11 Sep 2017 Results presented in a Syros Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top